| Terumo Introduces Its Smallest, Lowest Prime Volume, Full-Size Adult* Capiox® Oxygenator | https://www.terumo-europe.com/en-emea/news/terumo-introduces-its-smallest-lowest-prime-volume-full-size-adult-capiox®-oxygenator | Terumo Introduces Its Smallest, Lowest Prime Volume, Full-Size Adult* Capiox® Oxygenator | Ann Arbor, MICH. | 16/01/2019 23:00:00 | <p><span>Innovative technology improves patient care during cardiopulmonary bypass</span></p> |
| Major study investigating abbreviated DAPT post-Ultimaster DES in high bleeding risk patients reaches half-way mark | https://www.terumo-europe.com/en-emea/news/major-study-investigating-abbreviated-dapt-post-ultimaster-des-in-high-bleeding-risk-patients-reaches-half-way-mark | Major study investigating abbreviated DAPT post-Ultimaster DES in high bleeding risk patients reaches half-way mark | Leuven, Belgium | 09/01/2019 23:00:00 | <p style="text-align:left;"><em>Significant milestone achieved for global study likely to change DAPT guidelines</em></p><p style="text-align:justify;">December marked a significant milestone for a landmark study into the use of short duration dual anti-platelet therapy (DAPT) in HBR patients following stenting procedures, with patient recruitment reaching the half-way point.</p> |
| QuiremScout™, the first and only product indicated for SIRT work-up, receives CE mark | https://www.terumo-europe.com/en-emea/news/quiremscout™-the-first-and-only-product-indicated-for-sirt-work-up-receives-ce-mark | QuiremScout™, the first and only product indicated for SIRT work-up, receives CE mark | Leuven, Belgium | 06/01/2019 23:00:00 | <p>Terumo Europe today announced that QuiremScout™ has received CE mark, making it available for clinical centers throughout Europe. QuiremScout™ is designed to advance the SIRT work-up procedure. It does this by improving the accuracy of predicting lung shunting<sup>1</sup> and the intrahepatic distribution<sup>2</sup>, which aims to optimize SIRT patient selection and treatment planning. QuiremScout™ has been developed by Quirem Medical and will be exclusively distributed by Terumo.</p> |
| Terumo Announces European Launch of Biosimilar Using Terumo’s PLAJEX™ Pre-fillable Syringes | https://www.terumo-europe.com/en-emea/news/terumo-announces-european-launch-of-biosimilar-using-terumo’s-plajex™-pre-fillable-syringes | Terumo Announces European Launch of Biosimilar Using Terumo’s PLAJEX™ Pre-fillable Syringes | Tokyo, Japan | 06/12/2018 23:00:00 | <p style="text-align:justify;">Terumo Corporation (TSE: 4543) today announced that a biosimilar, which uses the company's PLAJEX™ pre-fillable syringe, has launched in Europe. Terumo manufactures the product Hulio®, a biosimilar to Humira® (adalimumab), on contract. This marks an important milestone, as the first overseas commercial launch for PLAJEX™.</p> |
| GMP Certification Awarded for the Manufacturing and Filling of Premixed Intravenous Solutions from the FDA (U.S.A.) | https://www.terumo-europe.com/en-emea/news/gmp-certification-awarded-for-the-manufacturing-and-filling-of-premixed-intravenous-solutions-from-the-fda-(u-s-a-) | GMP Certification Awarded for the Manufacturing and Filling of Premixed Intravenous Solutions from the FDA (U.S.A.) | Tokyo, Japan | 13/11/2018 23:00:00 | <p style="text-align:justify;">Terumo Corporation (TSE: 4543) today announced that its Kofu Pharmaceutical Plant in Japan has been conferred Good Manufacturing Practice (GMP) certification on October 18, by the U.S.A. Food and Drug Administration (FDA) for the manufacturing and filling of premixed intravenous solutions.</p> |
